Merck , one of the most recognizable names in the pharmaceutical industry, is devoted to the development of new drugs that can treat a wide range of afflictions, from diabetes to cancer.
So why is it collaborating with technology giant Samsung?
Well, it's not quite what you think. Today, Merck announced a partnership with Samsung Bioepis, a joint venture between Samsung's biologics unit and biotech company Biogen Idec. In this video, health-care analyst Max Macaluso discusses the detai mls of this deal and how it fits into Merck's total business.
Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, the Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more -- and get a full year of free updates -- click here to claim your copy today.
The article Merck Is Collaborating With ... Samsung? originally appeared on Fool.com.
Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.